Skip to main content
. Author manuscript; available in PMC: 2013 Jun 21.
Published in final edited form as: N Engl J Med. 2011 Jun 11;364(24):2305–2315. doi: 10.1056/NEJMoa1014209

Table 1.

Clinical and phenotypical features of the 47 HCL patients

HCL Case BRAF V600E Sex Age at first diagnosis WBC count at first diagnosis (/mm3) Splenomegaly at first diagnosis Positivity of leukemic B cellsd Previous therapy
ANXA1 (IHC) CD25 CD11c CD103
1a yes M 62 2,470 no yes yes n.a. yes IFNh
2 yes M 47 9,400 yes n.a. yes yes yes none
3 yes F 41 3,760 yes yes n.a. yes yes RTXi
4 yes M 62 6,710 yes yes yes yes yes none
5 yes M 56 6,240 yes n.a. yes yes yes none
6 yes F 61 8,819 yes n.a. yes yes yes none
7 yes M 39 2,980 yes yes n.a. n.a. n.a. splenectomy, IFN, DCFj, 2-CDAk, RTX, 2-CDA
8b yes M 46 2,700 yes n.a. yes yes yes none
9 yes M 60 5,470 yes n.a. yes yes yes DCF, 2-CDA, splenectomy
10 yes M 33 4,120 yes n.a. yes yes yes none
11a yesc M 46 11,390 yes n.a. yes yes yes DCF, 2-CDA, splenectomy, IFN, FCRl, CHOPm, 2-CDA
12 yes F 68 5,300 no yes n.a. n.a. n.a. none
13 yes M 70 9,350 no n.a. yes yes yes none
14 yes M 48 2,100 no yes yes yes n.a. none
15 yes M 75 3,720 no yes n.a. yes n.a. none
16 yesc M 39 4,800 yes yes yes yes yes DCF, 2-CDA, RTX, splenectomy
17a yes M 61 2,500 yes yes n.a. n.a. n.a. none
18a yes M 63 1,300 yes yes n.a. n.a. n.a. none
19 yesc F 60 7,800 yes n.a. yes yes yes none
20 yes F 47 8,010 yes n.a. yes yes yes none
21 yes M 55 2,330 yes n.a. yes yes yes none
22 yes M 63 3,680 yes n.a. yes yes yes none
23 yes M 33 9,900 no yes yes yes yes none
24 yes F 68 2,900 yes yes n.a. yes pose none
25 yes M 59 4,880 yes yes n.a. yes posf none
26a yes F 79 2,900 yes yes n.a. n.a. n.a. none
27a yes M 57 1,300 yes yes n.a. n.a. n.a. none
28a yes M 72 2,000 yes yes n.a. n.a. n.a. none
29a yes M 74 9,300 yes yes n.a. n.a. n.a. splenectomy, IFN
30a yes M 71 7,400 yes yes n.a. n.a. n.a. splenectomy, IFN
31a yes M 52 1,300 yes yes n.a. n.a. n.a. none
32 yes M 66 51,000 n.a. n.a. yes yes yes none
33 yes M 52 n.a. n.a. n.a. yes yes yes none
34 yes M 80 24,600 n.a. n.a. yes yes yes 2-CDA
35 yes F 77 34,700 yes n.a. yes yes yes IFN
36 yes M 49 12,100 n.a. n.a. yes yes yes none
37 yes M 51 37,900 n.a. n.a. yes yes yes none
38 yes M 35 23,500 yes n.a. yes yes yesg none
39 yes M 45 7,800 n.a. n.a. yes yes yes none
40 yes F 49 18,900 n.a. n.a. yes yes yes none
41 yes M 44 2,610 yes n.a. yes yes yes IFN, DCF+IFN, 2-CDA, splenectomy
42 yes M 56 7500 yes n.a. yes yes yes none
43 yes M 48 14110 yes n.a. yes yes yes none
44 yes M 41 4170 yes yes n.a. n.a. n.a. none
45 yes F 41 3760 no yes n.a. n.a. n.a. RTX
46 yes M 56 36070 yes n.a. yes yes yes none
47 yesc M 67 39000 yes n.a. yes yes yes CTXn
a

These cases have also been previously studied by genome-wide expression profiling analysis (ref. 5);

b

This case corresponds to the index patient subjected to whole exome sequencing.

c

Present in a homozygous/hemizygous fashion;

d

ANXA1 was assessed at immunohistochemistry (IHC), whilst CD25, CD11c and CD103 were assessed at flow cytometry (n.a. denotes not available).

e

In 19% of leukemic cells;

f

In 22% of leukemic cells;

g

In 39% of leukemic cells;

h

Interferon;

i

Rituximab

j

Deoxycoformycin;

k

2-Chloro-deoxyadenosine;

l

Fludarabine, Cyclophosphamide, Rituximab;

m

Cyclophosphamide, Adriamycin, Vincristine, Prednisone;

n

Cyclophosphamide